Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04880772
Other study ID # 290723
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date July 15, 2021
Est. completion date July 13, 2023

Study information

Verified date September 2023
Source East Lancashire Hospitals NHS Trust
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

To determine whether exercise and nutrition prehabilitation improves patient outcomes after cancer surgery


Description:

Preliminary qualitative and quantitative studies suggest that there are benefits (reduced length of stay, improved cardiorespiratory function, reduced postoperative complications and improved quality of life) when prehabilitation is used with the context of cancer care. In 2017 Macmillian Cancer Support developed a strategic 'Evidence and Insight' review on prehabilitation. The outcome of this was to incorporate prehabilitation into routine cancer care and to develop principles and guidance for prehabilitation. This study aims to support this vision and answer some of the questions on the patients who are most likely to benefit from prehabilitation and to quantify some of these benefits by investigating the molecular processes that influence clinical changes This study primarily seeks to assess the cardiovascular and biological impact of prehabilitation (exercise, nutrition) on patients undergoing hepatobiliary and colorectal cancer surgery. The investigators aim to assess whether there is an improvement in various cardiopulmonary exercise testing (CPET) variables such as maximum oxygen consumption and anaerobic threshold. The investigators also aim to study the inflammatory cytokines associated with cancer and how these markers respond to exercise. These inflammatory markers are thought to play a role in influencing some clinical outcomes such as wound infection and recovery. The study will also assess secondary outcomes including hospital stay, post operative complications and quality of life. The investigators aim to better understand the biological relationship between anti-inflammatory cytokine levels and the previously mentioned outcomes by measuring and analysing these mediators and performing selected muscle biopsies.


Recruitment information / eligibility

Status Completed
Enrollment 42
Est. completion date July 13, 2023
Est. primary completion date July 13, 2023
Accepts healthy volunteers No
Gender All
Age group 18 Years to 85 Years
Eligibility Inclusion Criteria: - Aged 18-85 - Sex: male/female - Radiological/tissue cancer diagnosis - Curative cancer of the colon, rectum, colorectal liver metastases (CRLM) of 2 or more segments - elective surgery (planned a minimum of 3 weeks from the date of first clinic meeting) - Access to digital technology(mobile phone, tablet or laptop, home computer) to participate in supervised home exercise Exclusion Criteria: Exclusion - Palliative disease - Haematological malignancy - Pregnancy - Emergency surgery - Physically unable to undergo CPET - Part of any other trial with similar interventions unless previously agreed on with all CIs - synchronous disease (operation on HPB & colorectal cancers at the same operation) - No access to digital technology(smart phone, tablet, laptop or home computer)

Study Design


Intervention

Other:
Prehabilitation
exercise & multivitamin (nutritional/dietary advice)

Locations

Country Name City State
United Kingdom Royal Blackburn Hospital Blackburn

Sponsors (2)

Lead Sponsor Collaborator
East Lancashire Hospitals NHS Trust Lancaster University

Country where clinical trial is conducted

United Kingdom, 

References & Publications (1)

Lambert JE, Hayes LD, Keegan TJ, Subar DA, Gaffney CJ. The Impact of Prehabilitation on Patient Outcomes in Hepatobiliary, Colorectal, and Upper Gastrointestinal Cancer Surgery: A PRISMA-Accordant Meta-analysis. Ann Surg. 2021 Jul 1;274(1):70-77. doi: 10.1097/SLA.0000000000004527. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Anaerobic threshold (AT) measured in ml/kg/min and maximum oxygen consumption ( VO2 peak) measured in ml/kg/min Cardiopulmonary exercise Test (CPET) variables change in baseline AT & VO2 peak at 4 weeks
Primary Inflammatory cytokines IL6 IL10 in muscle and blood measured in pg/ml change in baseline cytokines at 4 weeks
Secondary Clavien-Dindo complication rates Grades I-IV Up to 30 days from the day of operation
Secondary Length of hospital stay measured in days Defined as duration of stay from date of operation to discharge 30 & 90-day mortality
Secondary Quality of life measures (Illness Perception Questionnaire) This questionnaire assesses perceptions on each of the five dimensions(Identity, Cause, Timeline, Consequences, Cure-Control) by asking patients for their own beliefs about their condition.
High scores on the identity, consequences, timeline acute/ chronic and cyclical subscales represent strongly held beliefs about the number of symptoms attributed, the negative consequences, and the chronicity and cyclical nature of the illness.
High scores on the identity and cure-control and coherence subscales represent positive beliefs about controllability and a personal understanding of the illness.
baseline and within 24 weeks after surgery
Secondary Hand Grip Strength measured in kg Measured by digital dynamometer baseline, immediately after the intervention, within 24 weeks after surgery
Secondary Quality of life measure (Mental Adjustment to Cancer Scale) Assessment of participants mental adjustment to a cancer diagnosis. Designed to measure Fighting Spirit (FS), Anxious Preoccupation (AP), Helpless-hopelessness (HH) and Fatalism. This is a 40-item measure of specific psychological (Coping) responses that cancer patients may display in the process of adjusting to the diagnosis and treatment of their disease.
A higher score represents higher endorsement of the adjustment response.
baseline and within 24 weeks after surgery
See also
  Status Clinical Trial Phase
Active, not recruiting NCT03781934 - A Study to Evaluate MIV-818 in Patients With Liver Cancer Manifestations Phase 1/Phase 2
Completed NCT02107755 - Stereotactic Radiation Therapy and Ipilimumab in Treating Patients With Metastatic Melanoma Phase 2
Recruiting NCT05057052 - Cryoablation Combined With Sintilimab Plus Regorafenib In Previously Treated Colorectal Cancer Liver Metastasis Phase 2
Recruiting NCT06120127 - Postoperative Chemotherapy With/Without Radiotherapy and Immunotherapy for Colorectal Liver Metastases With High Risk of Locally Recurrence Phase 2
Recruiting NCT04837885 - Intra-arterial Hepatic (IAH) Infusion of Radiolabelled Somatostatin Analogs in GEP-NET Patients With Dominant Liver Metastases Phase 2
Terminated NCT04589884 - Intraoperative EXamination Using MAChine-learning-based HYperspectral for diagNosis & Autonomous Anatomy Assessment
Not yet recruiting NCT04520737 - Multimodal Prehabilitation During Chemotherapy in Patients With Colorectal Liver Metastases N/A
Terminated NCT02465112 - Metabolic Radiotherapy After Complete Resection of Liver Metastases in Patient With Digestive Neuroendocrine Tumor Phase 3
Completed NCT02352259 - Treatment of Liver Metastases With Electrochemotherapy (ECTJ) Phase II Phase 2
Active, not recruiting NCT01763450 - Bevacizumab Therapy Untreated Unresectable Liver Metastases From Colorectal Cancer Phase 2
Withdrawn NCT01631539 - Chemoembolisation With CPT11 Loaded DC Bead With Cetuximab and 5FU/LV in First Line in Patients With KRAS Wildtype mCRC N/A
Recruiting NCT01250158 - Liver-PILP First-in-Man N/A
Terminated NCT01233544 - Radiofrequency Ablation Versus Stereotactic Radiotherapy in Colorectal Liver Metastases Phase 3
Completed NCT01347333 - Stereotactic Body Radiotherapy for Liver Tumors N/A
Completed NCT01683357 - Prognosis of One-stage Hepatectomy for Bilobar Colorectal Metastases N/A
Completed NCT00587756 - Alternative to Two-Stage Hepatectomy N/A
Completed NCT04942665 - Low Dose ICG for Biliary Tract and Tumor Imaging Phase 2
Not yet recruiting NCT05354674 - Multimodal Deep Learning Signature for Evaluation of Response to Bevacizumab in Patient With Colorectal Cancer Liver Metastasis
Recruiting NCT04616495 - Liver Transplantation in Patients With Unresectable Colorectal Liver Metastases
Not yet recruiting NCT04509635 - Cetuximab Re-challenge for Colorectal Cancer Liver Metastasis Phase 3

External Links